Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
By J. Lalezari, K. Henry, M. O'Hearn, J. Montaner, P. Piliero, B. Trottier, S. Walmsley, C. Cohen, D. Kuritzkes, J. Eron and 6 more. New England Journal of Medicine, 2003
916 citations recorded by the source corpus.
Subfields: Infectious Diseases, Virology
View Paper: https://www.semanticscholar.org/paper/11c56faafe328e96fab6748cc53346bda573f425
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
In Virology
Citations in the corpus
- British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008 (2005, background): “Clinical trials have repeatedly demonstrated the importance of the background regimen to support the activity of the new drugs [36–43].”
- Protein therapeutics: a summary and pharmacological classification (2008, background): “By binding to gp120/gp41 — the HIV envelope protein responsible for fusion of the virus with host cells — this 36-amino-acid peptide prevents the conformational change in gp41 that is required for viral fusion, and thereby inhibits viral entry into the cel”
- HIV-1 antiretroviral drug therapy. (2012, neutral): “7) (Kilby et al. 1998; Lalezari et al. 2003).”